Biogen Inc (NASDAQ: BIIB) is caught in more than one legal wrangle with generic companies over patents related to its key multiple sclerosis drug Tecfidera, which was approved by the FDA in March 2013.Following the West Virigina court's ruling, Biogen has filed a motion seeking an injunction to stop Mylan NV (NASDAQ: MYL) from launching a generic at risk, Harrison said.